What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

European Commission President Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences. Luellen shared the company's ambitious mission ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...